AnGes Inc

AnGes Inc maintains a strong liquidity position with a current ratio of 1.86 and a price-to-book ratio of 0.76, indicating that the company's market value is below its book value. The company holds JPY 1,820,743,000 in cash and equivalents, which is a significant portion of its total assets of JPY 27,675,479,000. The low debt-to-equity ratio of 0.01 suggests minimal leverage, reducing financial risk.

Profitability metrics are negative, with a return on equity of -6.58% and a return on assets of -6.06%, reflecting the company's ongoing losses. The operating income of -JPY 2,614,893,000 and net income of -JPY 1,676,419,000 indicate that the company is not currently generating positive earnings. The gross profit of JPY 76,148,000 is significantly lower than the operating expenses, contributing to the net loss.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may increase exposure to market-specific risks. The company's revenue of JPY 2,340,150,000 is derived from its core operations in regenerative medicine and cell therapy.

Looking ahead, the company's revenue is expected to remain under pressure, with no significant growth indicators in the current fiscal year. The operating cash flow of -JPY 4,251,797,000 and capital expenditure of -JPY 16,575,000 suggest that the company is investing in its operations but is not generating positive cash flow from operations. The absence of a clear growth trajectory raises concerns about the company's ability to achieve profitability in the near term.

Risk factors include the company's negative earnings and cash flow, which could impact its ability to fund operations and research and development activities. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's reliance on external financing to fund its operations remains a concern.

Recent events include the disclosure of the company's latest financial results, which show continued losses and negative cash flow. The company has not issued any new products or received regulatory approvals in the recent period, which may affect its future revenue potential. The absence of significant recent developments suggests that the company is in a development phase rather than a growth or maturity phase.

This is the first analysis for AnGes Inc (4563.T), meaning there is no prior basis for computing material changes or deltas in the company's profile. Consequently, no specific shifts in operational metrics, financial performance, or strategic direction can be identified from the available data. The company currently has a minimal presence in terms of market coverage and institutional tracking. There are three analysts covering the stock, but the company is not a member of any major indices. Additionally, there are no recorded top holders or officers listed in the current dataset, suggesting limited public disclosure or tracking of these specific entities. Market activity and sentiment signals have been virtually non-existent over the past month. From June 24, 2026, through July 14, 2026, daily dispatch counts were zero for nearly every day, with the sole exception of July 3, 2026, which recorded a single dispatch. No sentiment data is available for this period, indicating a lack of significant news flow or market commentary. Given the absence of material changes, watcher signals, or cross-source activity, there is no immediate catalyst or trend to analyze for investors. The lack of index membership and limited analyst coverage further underscores the low visibility of the stock in the current market landscape. Investors should monitor for future updates as more data becomes available to establish a baseline for performance and sentiment.

AnGes demonstrates best-in-class cash conversion at 2.54, significantly outperforming the cohort median of 0.87.

The company maintains a low dilution risk profile, suggesting limited immediate pressure on existing shareholder equity value.

Liquidity risk is assessed as low, implying the company currently faces minimal immediate threats to its operational continuity.

Debt-to-equity ratio of 0.01 matches the cohort median, reflecting a conservative leverage position relative to peers.

Operating margin of -11.17% falls significantly below the cohort median of -2.56%, highlighting poor operational profitability.

Net margin of -7.16% underperforms the cohort median of -2.38%, demonstrating weaker bottom-line performance than peers.

Revenue ¥203.8M, +20,4% YoY; Operating income −19,2% YoY.

• ▍Revenue ¥203.8M, +20,4% YoY
• ▍Operating income −19,2% YoY
• ▍Net income +13,2% YoY
• ▍Net margin -531.3%

Revenue ¥228.0M, +32,5% YoY; Operating income +92,8% YoY.

• ▍Revenue ¥228.0M, +32,5% YoY
• ▍Operating income +92,8% YoY
• ▍Net income +97,4% YoY
• ▍Net margin -235.5%

Revenue ¥231.2M, +86,3% YoY; Operating income +33,7% YoY.

• ▍Revenue ¥231.2M, +86,3% YoY
• ▍Operating income +33,7% YoY
• ▍Net income +80,2% YoY
• ▍Net margin -312.7%

Revenue ¥245.7M, +5,0% YoY; Operating income +56,2% YoY.

• ▍Revenue ¥245.7M, +5,0% YoY
• ▍Operating income +56,2% YoY
• ▍Net income −62,1% YoY
• ▍Net margin -1106.1%

Revenue ¥169.2M; Operating income -¥1.26B.

• ▍Revenue ¥169.2M
• ▍Operating income -¥1.26B
• ▍Net margin -737.3%

Revenue ¥172.0M; Operating income -¥22.16B.

• ▍Revenue ¥172.0M
• ▍Operating income -¥22.16B
• ▍Net margin -12192.5%

Revenue ¥124.1M; Operating income -¥1.72B.

• ▍Revenue ¥124.1M
• ▍Operating income -¥1.72B
• ▍Net margin -2947.4%

Revenue ¥234.0M; Operating income -¥2.61B.

• ▍Revenue ¥234.0M
• ▍Operating income -¥2.61B
• ▍Net margin -716.4%

Revenue ¥874.1M, +35,8% YoY; Operating income +82,4% YoY.

• ▍Revenue ¥874.1M, +35,8% YoY
• ▍Operating income +82,4% YoY
• ▍Net income +81,4% YoY
• ▍Free cash flow +79,1% YoY
• ▍Net margin -597.8%

Revenue ¥643.6M, +320,7% YoY; Operating income −111,9% YoY.

• ▍Revenue ¥643.6M, +320,7% YoY
• ▍Operating income −111,9% YoY
• ▍Net income −278,2% YoY
• ▍Free cash flow −462,1% YoY
• ▍Net margin -4370.3%

Revenue ¥153.0M, +128,1% YoY; Operating income +16,1% YoY.

• ▍Revenue ¥153.0M, +128,1% YoY
• ▍Operating income +16,1% YoY
• ▍Net income +49,5% YoY
• ▍Free cash flow +62,7% YoY
• ▍Net margin -4861.7%

Revenue ¥67.1M, +4,5% YoY; Operating income −4,1% YoY.

• ▍Revenue ¥67.1M, +4,5% YoY
• ▍Operating income −4,1% YoY
• ▍Net income −7,6% YoY
• ▍Free cash flow −4,4% YoY
• ▍Net margin -21942.4%